Clinical trial
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse…
NCT00238368 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00238368 |
|---|---|
| Title | Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant |
| Official title | Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone and 6 more |
| Enrollment | 59 |
| Start date | Feb 1, 2004 |
| Primary completion | Sep 17, 2007 |
| Completion | Sep 17, 2007 |
| First posted | Oct 13, 2005 |
| Last update posted | Nov 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: